Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Up 286.7% in July

Entera Bio Ltd. (NASDAQ:ENTX) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 1,150,114 shares, an increase of 286.7% from the July 15th total of 297,452 shares. Approximately 2.6% of the company’s stock are sold short. Based on an average daily trading volume, of 7,664,901 shares, the days-to-cover ratio is currently 0.2 days.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ENTX. Wall Street Zen raised shares of Entera Bio to a “sell” rating in a research report on Saturday, August 8th. HC Wainwright reissued a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Entera Bio has a consensus rating of “Hold” and a consensus target price of $9.00.

Entera Bio Price Performance

Shares of NASDAQ:ENTX opened at $2.89 on Friday. The business’s 50-day moving average is $2.01 and its 200 day moving average is $1.54. Entera Bio has a 1 year low of $0.91 and a 1 year high of $4.20. The firm has a market capitalization of $500.38 million, a P/E ratio of -8.26 and a beta of 1.38.

Entera Bio (NASDAQ:ENTX) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). On average, analysts expect that Entera Bio will post -0.34 EPS for the current year.

Hedge Funds Weigh In On Entera Bio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC grew its position in Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after purchasing an additional 28,322 shares during the last quarter. HighTower Advisors LLC increased its stake in Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after purchasing an additional 25,000 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Entera Bio by 22.2% in the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after buying an additional 19,601 shares during the last quarter. Jane Street Group LLC raised its holdings in shares of Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after buying an additional 43,536 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its stake in shares of Entera Bio by 5.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after buying an additional 29,629 shares during the period. 14.11% of the stock is owned by hedge funds and other institutional investors.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.